timothy sykes logo
IBRX Stock Extends Rally As Traders Bet On Oncology Momentum Thumbnail
G Google News

IBRX Stock Extends Rally As Traders Bet On Oncology Momentum

ELLIS HOBBS•UPDATED OCT. 9, 2026, 12:32 PM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

ImmunityBio Inc. surges as pivotal clinical progress drives bullish sentiment, and stocks have been trading up by 7.82 percent.

Key Takeaways

  • Shares are up 12.4%, or $1.15, with ImmunityBio trading around $10.43 after a string of news‑driven gains.
  • The stock recently jumped 11.6% intraday to $10.36, signaling aggressive momentum trading in IBRX.
  • An upcoming Piper Sandler Virtual Oncology Symposium fireside chat will spotlight ANKTIVA and ImmunityBio’s broader immunotherapy pipeline.
  • Executive chairman Patrick Soon‑Shiong is leading a PIPE financing into PDS Biotechnology and joining PDSB’s board, hinting at a wider oncology ecosystem around ImmunityBio.
  • Recent Form 4 insider filings show ownership changes in IBRX, but without details on size or direction, the trading signal remains unclear.

Candlestick Chart

Live Update At 12:32:30 EDT: On Friday, October 09, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 7.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio, trading under ticker IBRX, has been acting like a textbook momentum name on the chart while still looking like a classic development‑stage biotech in the fundamentals. Over the last several weeks, IBRX has pushed from the high‑$7s and low‑$8s to close at $10.69 on 2026/10/09, with a series of higher lows and strong pushes over $10. That steady grind higher sets the stage for the recent 12.4% spike to $10.43 and the earlier 11.6% run to $10.36 in the same news cycle.

Under the hood, this is still a heavy‑loss story. IBRX generated about $113.3M in revenue, but carries profit margins deeply in the red and an EBITDA of roughly -$194.7M in the latest reported quarter. Net income from continuing operations came in at about -$230.4M, and free cash flow was roughly -$70.0M.

More Breaking News

The balance sheet shows cash and short‑term investments around $357.4M, with a current ratio of 5.7, so near‑term liquidity looks solid even as ImmunityBio burns cash. For traders, that mix — big losses, big pipeline, decent cash — often translates into binary, headline‑driven price action. IBRX fits that mold perfectly right now.

Why Traders Are Watching IBRX Right Now

IBRX has earned a front‑row seat on momentum screens after back‑to‑back double‑digit percentage moves. A 12.4% jump to about $10.43 in the latest session, stacked on top of an earlier 11.6% surge to $10.36, tells you traders are swarming around ImmunityBio’s tape. This is the kind of action day traders and swing traders on platforms like StocksToTrade look for — strong trend, clean levels, and clear catalysts.

One main catalyst on the radar is ImmunityBio’s upcoming appearance at a Piper Sandler Virtual Oncology Symposium. Founder and executive chairman Patrick Soon‑Shiong is set to discuss ANKTIVA and the broader immunotherapy pipeline. That type of event does not change the cash flow overnight, but it does shape the story. When a biotech like IBRX is priced more on future potential than current earnings, narrative can move the stock just as much as numbers. Traders will be tuned in for any fresh clues on trial progress, regulatory direction, or commercialization timelines.

There is also a strategic subplot developing around Soon‑Shiong himself. He is leading a PIPE financing into PDS Biotechnology and joining PDSB’s board. That does not alter ImmunityBio’s fundamentals today, but it signals he is building an oncology ecosystem that could benefit IBRX down the road through science sharing, trial designs, or potential collaborations. For traders, that is optional upside — not something to chase blindly, but worth tracking as part of the long‑term story.

Layered on top are recent Form 4 filings showing changes in beneficial ownership of ImmunityBio shares. Because the filings do not say whether insiders bought or sold or how much, the signal is neutral at best. Active traders in IBRX will note the activity but lean more on price action and catalysts than on incomplete insider data.

Conclusion

ImmunityBio is trading like a classic high‑beta biotech — volatile, liquid, and glued to the headlines. The recent run from the $8 area to a close of $10.69, plus intraday spikes above $10.40, shows strong demand for IBRX whenever news hits the tape. At the same time, the financials remind everyone this is a high‑risk development story: steep losses, negative earnings, and a price‑to‑sales ratio north of 60 as traders pay up for future potential, not current profits.

The upcoming Piper Sandler oncology fireside chat gives ImmunityBio another stage to sell its ANKTIVA story and broader pipeline vision. If the tone is confident and the details sound de‑risked, traders may keep rewarding IBRX with higher prices. If the update underwhelms, momentum‑style names like this can unwind just as fast as they ran. Meanwhile, Soon‑Shiong’s PIPE into PDS Biotechnology and his new board seat there broaden the oncology network around ImmunityBio, adding a strategic wrinkle for longer‑term watchers of IBRX.

For active traders, the lesson is the same one Tim Sykes pounds into students: “Volatile stocks with big stories can change your life or wreck your account — the difference is whether you cut losses quickly and trade the pattern, not the hype.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” IBRX is giving plenty of patterns right now. The key is to treat it as a trading vehicle, do your own research, and never confuse educational analysis with advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”